Evidence map›Paper›PMID 24827833›Full record

ArticlePloS one2014

The prevalence of species and strains in the human microbiome: a resource for experimental efforts.

Laurens Kraal, Sahar Abubucker, Karthik Kota, Michael A Fischbach, Makedonka Mitreva

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Life (Basel, Switzerland) · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. An Update on the Role and Potential Molecules in Relation toDiabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Review
  18. Microbiology spectrum · 2023
    Article
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Laurens KraalDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, United States of America; California Institute for Quantitative Biosciences, University of California San Francisco, San Francisco, California, United States of America.
Sahar AbubuckerThe Genome Institute, Washington University School of Medicine, Saint Louis, Missouri, United States of America.
Karthik KotaThe Genome Institute, Washington University School of Medicine, Saint Louis, Missouri, United States of America.
Michael A FischbachDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, United States of America; California Institute for Quantitative Biosciences, University of California San Francisco, San Francisco, California, United States of America.
Makedonka MitrevaThe Genome Institute, Washington University School of Medicine, Saint Louis, Missouri, United States of America; Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, United States of America; Department of Genetics, Washington University School of Medicine, Saint Louis, Missouri, United States of America.

Funding

Large Scale Genome SequencingU54HG003079 · NHGRI · WASHINGTON UNIVERSITY · PI DUTCHER, SUSAN K · 2004 to 2016
$445.7M
Rewiring Therapeutic Cells: User-Controlled T Cells and Stem CellsP50GM081879 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIM, WENDELL A · 2010 to 2017
$19.0M
Sequencing the Human MicrobiomeU54HG004968 · NHGRI · WASHINGTON UNIVERSITY · PI WILSON, RICHARD K. · 2009 to 2012
$16.7M
BMI Bioinformatics Training GrantsT32GM067547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HERNANDEZ, RYAN D. · 2003 to 2022
$6.6M
Integrative Program in Complex Biological System (ipCBS)T32EB009383 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARSHALL, WALLACE, WEINER, ORION D · 2009 to 2022
$3.2M
Identifying and characterizing small molecules from the human microbiomeDP2OD007290 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FISCHBACH, MICHAEL ANDREW · 2010 to 2010
$2.3M
NHGRI NIH HHS U54 HG003079NHGRI NIH HHS U54 HG004968NHGRI NIH HHS U54HG004968NIBIB NIH HHS T32 EB009383NIGMS NIH HHS P50 GM081879NIGMS NIH HHS T32 GM067547NIH HHS DP2 OD007290
6 · The paper itself

Abstract

Experimental efforts to characterize the human microbiota often use bacterial strains that were chosen for historical rather than biological reasons. Here, we report an analysis of 380 whole-genome shotgun samples from 100 subjects from the NIH Human Microbiome Project. By mapping their reads to 1,751 reference genome sequences and analyzing the resulting relative strain abundance in each sample we present metrics and visualizations that can help identify strains of interest for experimentalists. We also show that approximately 14 strains of 10 species account for 80% of the mapped reads from a typical stool sample, indicating that the function of a community may not be irreducibly complex. Some of these strains account for >20% of the sequence reads in a subset of samples but are absent in others, a dichotomy that could underlie biological differences among subjects. These data should serve as an important strain selection resource for the community of researchers who take experimental approaches to studying the human microbiota.

Indexed as

Genome, BacterialHumansMetagenomeMetagenomicsMicrobiotaPhylogenyPrevalenceRNA, Ribosomal, 16SSequence Analysis, DNARNA, Ribosomal, 16S

Identifiers

PMID24827833
PMCPMC4020798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.